Cardinal Health opened The Center for the Advancement of Molecular Imaging (The Center) – a new, first-of-its-kind collaboration laboratory that will expedite the development of nuclear imaging agents that treat complex diseases like cancer, heart disease and neurological disorders.
Cardinal Health’s industry-leading scientists, engineers and manufacturing experts will leverage state-of-the-art technology and infrastructure at the newly renovated and expanded 25,000-square-foot campus to help pharmaceutical companies and academic research institutions accelerate the development, testing and commercialisation of new radiopharmaceuticals and positron emission tomography imaging agents. They will also leverage The Center to improve the manufacturing and dispensing process for imaging agents.
“The launch of The Center for the Advancement of Molecular Imaging is a strategic investment in the future of the molecular imaging and pharmaceutical industries,” said John Rademacher, president of Cardinal Health’s Nuclear and Pharmacy Services. “By helping pharmaceutical companies and academic research institutions accelerate innovation and reduce the time it takes to get new imaging agents to market, we can more accurately diagnose diseases earlier in their onset. Ultimately, our goal is also to drive better patient outcomes by helping physicians track how well patients are responding to treatments.”
The Center will also house stand-alone laboratory space to allow the company’s partners to conduct confidential radiopharmaceutical and positron emission tomography biomarker experiments. It will also provide access to the quality and regulatory expertise that is critical to earning FDA approval of new imaging agents, and will house a global training facility for Cardinal Health’s Nuclear Pharmacy Services business.